PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

Inclusion Criteria:

• Diagnosis of COVID-19 by lab test within 5 days of study participation

Exclusion Criteria:

• Allergy to "iodine," shellfish, or food dye
• Receiving intranasal steroids
• Sinus surgery within 30 days of beginning the study
• Intubated at the time of enrollment
• Pregnancy
• Participation in other COVID-19 studies - to be determined on a case by case basis